drugset / Trial / NCT02741739
Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects
RandomizedParallel-groupOpen-labelBasic science
Summary
Primary Objective: Determine blood concentrations of two formulations of REGN1033. Secondary Objective: Assess safety and tolerability of REGN1033.
Timeline
- Start
- 2016-03
- Primary completion
- 2016-04
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trevogrumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.